Abstract: A process for metathesis of olefins, bringing olefins into contact with a catalyst activated by heating to a temperature in the range 100° C. to 1000° C. in an atmosphere of non-reducing gas, the catalyst containing at least one inorganic material having at least two elementary spherical particles, each of which are metal oxide particles with a size of at most 300 nm and containing at least one of tungsten, molybdenum, rhenium, cobalt, tin, ruthenium, iron or titanium, alone or a mixture, the metal oxide particles being present within a mesostructured matrix of an oxide of at least one element Y: silicon, aluminium, titanium, tungsten, zirconium, gallium, germanium, tin, antimony, lead, vanadium, iron, manganese, hafnium, niobium, tantalum, yttrium, cerium, gadolinium, europium or neodymium or a mixture thereof, the matrix having pore size 1.5 to 50 nm and amorphous walls with thickness 1 to 30 nm and maximum diameter of 200 ?m.

Abstract: The method for catalytic conversion of alcohols according to the present invention using a zinc oxide catalyst comprises a thermal pretreatment stage in an inert and/or reducing atmosphere at a temperature of at least 100° C., prior to the reaction stage.

Abstract: A hydridable alloy of formula R1-x-yMgxMyNis-aBa wherein R is selected from the group consisting in rare earths, yttrium and a mixture thereof; M represents Zr and/or Ti; B is selected from the group consisting in Mn, Al, Co, Fe and a mixture thereof; 0.1<x<0.4; 0?y<0.1; 3<s<4.5 and 0?a<1; at least 5% of the volume of which consists of a stack of sequences of a pattern of the A2B4 type and of n patterns of the CaCu5 type randomly distributed along one direction, n being an integer comprised between 1 and 10 and representing the number of patterns of the CaCu5 type per pattern of the A2B4 type. A method for making a hydridable alloy comprising steps for compression and applying a current through a mixture comprising Mg2Ni and a compound comprising nickel and one or several elements selected from the group consisting in rare earths and yttrium.

Abstract: The method for catalytic conversion of alcohols according to the present invention using a zinc oxide catalyst comprises a thermal pretreatment stage in an inert and/or reducing atmosphere at a temperature of at least 100° C., prior to the reaction stage.

Abstract: The invention relates to a method of synthesizing heterocyclic compounds. The invention is characterised in that it consists in opening a compound having formula (I), wherein: —X represents NH, O, S or a N-p group, p being a protective group, such as Boc or Troc; —Y represents N, O, S; —Z represents NH2 or NH-p; and —R1 represents a C1-C6 alkoxy radical, aryloxy, such as phenyloxy, or a pyrrolyl radical, said radicals being optionally substituted, or the salts thereof, and the isomers of the aforementioned compounds. Moreover, the above-mentioned opening step is performed in conditions such as to produce a heterocycle having formula (II), wherein: —X, Y and Z are as defined above; —R2 represents a —CH?CH—CH2—NH—COR1 or —CH?CH—CH2—NH—CO group; and R3 occupies one, two or three positions and represents a halogen. The invention can be used to synthesise natural products.

Abstract: A composition comprises an aqueous dispersion of particles (p) of mean hydrodynamic diameter between 50 and 5000 nm. The particles contain (A) polymers based on cyclodextrin units, comprising on average at least four cyclodextrin units within their structure; and (B) macromolecules of polysaccharides comprising groups G capable of forming inclusion complexes with the cyclodextrins present in the structure of the polymers (A), with an average number of groups G per polysaccharide macromolecule at least equal to three. The compounds (A) and (B) are water-soluble in the isolated state. A method is also provided which relates to the preparation of these compositions, as well as their use in order to achieve the encapsulation of compounds such as active substances.

Abstract: A vacuum magnetic ion trap includes an assembly forming a permanent magnet including at least two magnetized structures (30, 32) in the form of hollow cylinders, one convergent radial structure, magnetized along a convergent radial direction, and one divergent radial structure, magnetized along a divergent radial direction, the convergent and divergent radial magnetized structures (30, 32) being arranged along a common longitudinal axis (XX?) The trap also includes a sealed chamber (4) containing anion confinement cell (8) fixed between the at least two magnetized structures (30, 32) and including at least two trapping electrodes (10) connectable to a voltage generator (12).

Abstract: The invention relates to the use of 8-hydroxyquinoline 7-carboxylic acid derivatives in order to produce integrase-inhibiting medicaments, capable of blocking viral replication in the stages preceding integration, and if appropriate at the level of this integration stage, these medicaments being usable for the treatment of retroviral pathologies, in particular for the treatment of AIDS.

Abstract: The invention concerns a vacuum magnetic ion trap comprising an assembly forming a permanent magnet including at least two magnetized structures (30, 32) in the form of hollow cylinders, one convergent radial structure, magnetized along a convergent radial direction, and one divergent radial structure, magnetized along a divergent radial direction, said convergent and divergent radial magnetized structures (30, 32) being arranged along a common longitudinal axis (XX?). Said trap also comprises a sealed chamber (4) containing an ion confinement cell (8) fixed between said at least two magnetized structures (30, 32) and including at least two trapping electrodes (10) connectable to a voltage generator (12).

Abstract: A magnetoresistive memory element including a trapped magnetic region and a free magnetic region separated by a barrier layer. The free magnetic region comprises a stacking of at least two antiferromagnetically-coupled ferromagnetic layers, a layer magnetic moment vector being associated with each layer, the resulting magnetic moment vector, equal to the sum of the layer magnetic moment vectors, having an amplitude smaller than at least 40% of the amplitude of the layer magnetic moment vector of maximum amplitude. The anisotropy field and/or the demagnetizing field tensor is not identical for the at least two ferromagnetic layers, whereby the angular deviations of the layer magnetic moment vectors are different at the time of the application of an external magnetic field, which enables at least two methods for directly writing into the memory element, as well as its initialization.

Abstract: A magnetoresistive memory element including a trapped magnetic region and a free magnetic region separated by a barrier layer. The free magnetic region comprises a stacking of at least two antiferromagnetically-coupled ferromagnetic layers, a layer magnetic moment vector being associated with each layer, the resulting magnetic moment vector, equal to the sum of the layer magnetic moment vectors, having an amplitude smaller than at least 40% of the amplitude of the layer magnetic moment vector of maximum amplitude. The anisotropy field and/or the demagnetizing field tensor is not identical for the at least two ferromagnetic layers, whereby the angular deviations of the layer magnetic moment vectors are different at the time of the application of an external magnetic field, which enables at least two methods for directly writing into the memory element, as well as its initialization.

Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition comprising encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-angiogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.

Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition comprising encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-angiogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.

Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition comprising encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-angiogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.

Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition comprising encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-angiogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.

Abstract: Compositions and methods for reducing ocular diseases by implanting in an eye of a subject a composition encapsulated cells which produce polypeptides, more particularly polypeptides that exhibit neurotrophic and/or anti-anglogenic activity. The encapsulation prevents the entry of host immune cells in the microcapsule while permitting the release of the polypeptide outside of the microcapsule.

Abstract: This medicinal composition for the treatment and prevention of the symptoms of heart failure contains, by way of active principle, at least one compound chosen from 2-amino-1-(2,5-dimethoxyphenyl)-1-propanol (methoxamine) and its pharmaceutically acceptable salts, and it is presented in a form which can be administered by inhalation (aerosol or nebulizate).It was demonstrated, in particular, that the administration of methoxamine-HCl by inhalation, at a unit dosage of 10 mg, in the form of a 2% (w/v) solution in physiological saline, decreases airways resistance in subjects suffering from decompensated left ventricular failure, and increases the exertion tolerance of patients suffering from compensated left vetricular failure, whether the latter is of ischemic origin or otherwise.

Abstract: An ion source is described, including a source of neutral particles which arrive at an ionization support positioned inside a chamber which is closed by a cap and which includes lateral walls. The cap includes an outlet orifice opposite which a plate defines a main ionization active surface. An electric field is applied between said device and by an electrode place downstream from the orifice in the direction of ion emission and fitted with a corresponding opening. Overall, the ionization support defines, by virtue of its active surface, and by virtue of holes surrounding said central active surface, a baffle assembly which prevents neutral atoms from passing directly to the outlet orifice, and which contributes to a high degree of ionization.

Abstract: Between the electrostatic sector (SE 23) and the magnetic sector (SM 30) of a mass spectrometer, there is provided a quadrupole (QP 26) which applies parallel beams to the magnetic sector whose inclination depends on the energy dispersion of the particles. A slotted lens (LF 27) corrects the divergence of the quadrupole in the perpendicular plane. A suitable relationship between the angle of the inlet face of the magnetic sector (SM 30) and the deflection angle provided thereby ensures that the second order aperture aberrations of the magnetic sector are corrected. The chromatic aberrations may be corrected by means of a hexapole (HP 25) centered on the focus of the quadrupole (QP 26). Another hexapole (HP 22) placed upstream from the electrostatic sector (SE 23) level with a constriction in vertical section of the particle beam serves to correct second order aperture aberrations related to the electrostatic sector (SE 23).